Zhejiang Medicine chairman proposes share repurchase plan

Zhejiang Medicine (SSE:600216) announced that its Chairman, Li Nanxing, has proposed a share repurchase plan utilizing either the company's own funds or self-raised funds. The repurchase will be executed through centralized competitive bidding via the Shanghai Stock Exchange, targeting a portion of the company’s issued A-shares. The primary motivation behind the repurchase is confidence in the company's sustained and stable growth, and recognition of its intrinsic value.